The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer's Disease

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Beta-amyloid (Aβ) 1-42, initially identified as Amyloid A4 protein, is central to Alzheimer's disease (AD) research.
• The traditional Beta Amyloid Cascade hypothesis viewed Aβ as a toxic molecule, overlooking its physiological roles.
• Therapeutic strategies have focused on reducing all Aβ forms, despite weak correlations between plaques and cognitive decline.

Purpose of the Study:

• To introduce the Beta Amyloid Dysfunction (BAD) hypothesis, offering an alternative to the Beta Amyloid Cascade hypothesis.
• To explain the failure of certain AD therapeutic approaches, including BACE and Gamma-secretase inhibitors.
• To provide a new framework for developing effective AD treatments targeting Aβ homeostasis.

Main Methods:

• Review and reinterpretation of existing data on Aβ pathology and its physiological roles.
• Conceptual development of the BAD hypothesis based on Aβ monomer homeostasis in the synaptic vesicle cycle.
• Analysis of clinical trial outcomes in light of the proposed BAD hypothesis.

Main Results:

• The BAD hypothesis posits that early AD pathology stems from disturbed Aβ monomer homeostasis, leading to toxic oligomers.
• This dysfunction explains the inefficacy of therapies targeting total Aβ reduction or secretase inhibition.
• The hypothesis highlights the importance of physiological Aβ monomer function in synaptic regulation.

Conclusions:

• The BAD hypothesis offers a novel explanation for AD pathogenesis and therapeutic failures.
• It suggests that targeting Aβ homeostasis, rather than just reduction, is crucial for effective AD treatment.
• Further research is needed to fully elucidate the role of physiological Aβ monomer in AD.